MCF-7

Last updated
MCF-7 Cells MCF-7 Cells.jpg
MCF-7 Cells

MCF-7 is a breast cancer cell line isolated in 1970 from a 69-year-old White woman. [1] MCF-7 is the acronym of Michigan Cancer Foundation-7, referring to the institute in Detroit where the cell line was established in 1973 by Herbert Soule and co-workers. [2] The Michigan Cancer Foundation is now known as the Barbara Ann Karmanos Cancer Institute. [3]

Contents

Prior to MCF-7, it was not possible for cancer researchers to obtain a mammary cell line that was capable of living longer than a few months. [4]

The patient, Frances Mallon died in 1970 due to metastatic breast cancer. [5] Her cells were the source of much of current knowledge about breast cancer. [2] [6] At the time of sampling, she was a nun in the convent of Immaculate Heart of Mary in Monroe, Michigan under the name of Sister Catherine Frances.

MCF-7 and two other breast cancer cell lines, named T-47D and MDA-MB-231, account for more than two-thirds of all abstracts reporting studies on mentioned breast cancer cell lines, as concluded from a Medline-based survey. [7] MCF-7 has potential for new drug development, including anti-cancer drug testing, anti-estrogen drug resistance and antiplatelet drug development. [8]

Characteristics of MCF-7 cells

MCF-7 cells have the following characteristics: [2] [6] [7] [9] [10] [11]

This cell line retained several characteristics of differentiated mammary epithelium, including the ability to process estradiol via cytoplasmic estrogen receptors and the capability of forming domes.[ citation needed ]

Tumor necrosis factor alpha (TNF alpha) inhibits the growth of MCF-7 breast cancer cells. Treatment with anti-estrogens can modulate the secretion of insulin-like growth factor binding proteins. Omega-3 and 6 fatty acids such as EPA, DHA and AA has been reported to inhibit MCF-7 cell line growth and proliferation. [14]

PIK3CA helical mutations were identified in MCF-7, [15] but with low AKT activation. [16]

Related Research Articles

<span class="mw-page-title-main">Mammary gland</span> Exocrine gland in humans and other mammals

A mammary gland is an exocrine gland in humans and other mammals that produces milk to feed young offspring. Mammals get their name from the Latin word mamma, "breast". The mammary glands are arranged in organs such as the breasts in primates, the udder in ruminants, and the dugs of other animals. Lactorrhea, the occasional production of milk by the glands, can occur in any mammal, but in most mammals, lactation, the production of enough milk for nursing, occurs only in phenotypic females who have gestated in recent months or years. It is directed by hormonal guidance from sex steroids. In a few mammalian species, male lactation can occur. With humans, male lactation can occur only under specific circumstances.

<span class="mw-page-title-main">V. Craig Jordan</span> American-British pharmacologist (1947–2024)

Virgil Craig Jordan,, was an American and British scientist specializing in drugs for breast cancer treatment and prevention. He was Professor of Breast Medical Oncology, and Professor of Molecular and Cellular Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas. Previously, he was Scientific Director and Vice Chairman of Oncology at the Lombardi Comprehensive Cancer Center of Georgetown University. Jordan was the first to discover the breast cancer prevention properties of tamoxifen and the scientific principles for adjuvant therapy with antihormones. His later work branched out into the prevention of multiple diseases in women with the discovery of the drug group, selective estrogen receptor modulator (SERMs). He later worked on developing a new Hormone Replacement Therapy (HRT) for post-menopausal women that prevents breast cancer and does not increase the risk of breast cancer.

Marc Guy Albert Marie Lacroix is a Belgian biochemist and a researcher who specializes in breast cancer biology, metastasis and therapy.

<span class="mw-page-title-main">Nuclear receptor coactivator 3</span> Protein found in humans

The nuclear receptor coactivator 3 also known as NCOA3 is a protein that, in humans, is encoded by the NCOA3 gene. NCOA3 is also frequently called 'amplified in breast 1' (AIB1), steroid receptor coactivator-3 (SRC-3), or thyroid hormone receptor activator molecule 1 (TRAM-1).

<span class="mw-page-title-main">Risk factors for breast cancer</span> Overview article

Risk factors for breast cancer may be divided into preventable and non-preventable. Their study belongs in the field of epidemiology. Breast cancer, like other forms of cancer, can result from multiple environmental and hereditary risk factors. The term environmental, as used by cancer researchers, means any risk factor that is not genetically inherited.

<span class="mw-page-title-main">Insulin receptor substrate 1</span> Protein found in humans

Insulin receptor substrate 1(IRS-1) is a signaling adapter protein that in humans is encoded by the IRS1 gene. It is a 180 kDa protein with amino acid sequence of 1242 residues. It contains a single pleckstrin homology (PH) domain at the N-terminus and a PTB domain ca. 40 residues downstream of this, followed by a poorly conserved C-terminus tail. Together with IRS2, IRS3 (pseudogene) and IRS4, it is homologous to the Drosophila protein chico, whose disruption extends the median lifespan of flies up to 48%. Similarly, Irs1 mutant mice experience moderate life extension and delayed age-related pathologies.

<span class="mw-page-title-main">GATA3</span> Protein-coding gene in the species Homo sapiens

GATA3 is a transcription factor that in humans is encoded by the GATA3 gene. Studies in animal models and humans indicate that it controls the expression of a wide range of biologically and clinically important genes.

<span class="mw-page-title-main">Arzoxifene</span> Chemical compound

Arzoxifene is a selective estrogen receptor modulator (SERM) of the benzothiophene group which was never marketed. It is a potent estrogen antagonist in mammary and uterine tissue while acting as an estrogen agonist to maintain bone density and lower serum cholesterol. Arzoxifene is a highly effective agent for prevention of mammary cancer induced in the rat by the carcinogen nitrosomethylurea and is significantly more potent than raloxifene in this regard. Arzoxifene is devoid of the uterotrophic effects of tamoxifen, suggesting that, in contrast to tamoxifen, it is unlikely that the clinical use of arzoxifene will increase the risk of developing endometrial carcinoma.

<span class="mw-page-title-main">Galangin</span> Chemical compound

Galangin is a flavonol, a type of flavonoid.

<span class="mw-page-title-main">ZNF703</span> Protein-coding gene in the species Homo sapiens

ZNF703 is a gene which has been linked with the development of breast cancers. ZNF703 is contained within the NET/N1z family responsible for regulation of transcription essential for developmental growth especially in the hindbrain. Normal functions performed by ZNF703 include adhesion, movement and proliferation of cells. ZNF703 directly accumulates histone deacetylases at gene promoter regions but does not bind to functional DNA.

Patient derived xenografts (PDX) are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse. It is a form of xenotransplantation. PDX models are used to create an environment that allows for the continued growth of cancer after its removal from a patient. In this way, tumor growth can be monitored in the laboratory, including in response to potential therapeutic options. Cohorts of PDX models can be used to determine the therapeutic efficiency of a therapy against particular types of cancer, or a PDX model from a specific patient can be tested against a range of therapies in a 'personalized oncology' approach.

<span class="mw-page-title-main">T-47D</span> Human breast cancer cell line

T-47D is a human breast cancer cell line commonly used in biomedical research involving the hormonal expression of cancer cells.

<span class="mw-page-title-main">D-15414</span> Chemical compound

D-15414 is a nonsteroidal weak estrogen of the 2-phenylindole group which was never marketed. It is the major metabolite of the selective estrogen receptor modulator (SERM) zindoxifene (D-16726). D-15414 has high affinity for the estrogen receptor (ER) and inhibits the growth of ER-positive MCF-7 breast cancer cells in vitro. However, contradictorily, subsequent research found that the drug produced fully estrogenic effects in vitro similarly to but less actively than estradiol, with no antiestrogenic activity observed. The reason for the discrepancy between the findings is unclear, though may be due to methodology. The unexpected estrogenic activity of D-15414 may be responsible for the failure of zindoxifene in clinical trials as a treatment for breast cancer.

<span class="mw-page-title-main">MiR-206</span>

MiR-206 is a microRNA with a sequence conserved across most mammalian species, and in humans is a member of the myo-miR family of miRNAs, which includes miR-1, miR-133, and miR-208a/b. Mir-206 is well established for the regulation of cellular processes involving skeletal muscle development, as well as mitochondrial functioning. miR-206 is studied in C2C12 myoblast cells as this is a widely used model for the study of cellular differentiation of skeletal muscle. The biogenesis of miR-206 is unique in that the primary mature transcript is generated from the 3p arm of the precursor microRNA hairpin rather than the 5p arm. Currently, miR-206 has approximately twelve miRNA family members, and the cognate seed sequence of the miR-206 family is conserved across all twelve miRNA members.

<span class="mw-page-title-main">4T1</span>

4T1 is a breast cancer cell line derived from the mammary gland tissue of a mouse BALB/c strain. 4T1 cells are epithelial and are resistant to 6-thioguanine. In preclinical research, 4T1 cells have been used to study breast cancer metastasis as they can metastasize to the lung, liver, lymph nodes, brain and bone. The cells are known to be highly aggressive in live tissues.

<span class="mw-page-title-main">ERX-11</span> Chemical compound

ERX-11, also known as ERα coregulator-binding modulator-11, is a novel antiestrogen and experimental hormonal antineoplastic agent which is being researched for the potential treatment of estrogen receptor-positive breast cancer. It is not a competitive antagonist of the estrogen receptor (ER) like conventional antiestrogens such as tamoxifen or fulvestrant; instead of binding to the ligand-binding site of the ER, ERX-11 interacts with a different part of the ERα and blocks protein–protein interactions of the ERα with coregulators that are necessary for the receptor to act and regulate gene expression. It was designed to bind to the coregulator binding region of the ERα and inhibit the ERα/coactivator interaction, although its precise binding site and mode of action have yet to be fully elucidated and understood. Nonetheless, it is clear that ERX-11 binds within the AF-2 domain of the ERα.

<span class="mw-page-title-main">Relda Marie Cailleau</span> American scientist

Relda Marie Cailleau was an American scientist primarily known for her establishment of a series of breast cancer cell lines that have been crucial to the discovery of anticancer drugs and to an understanding of breast cancer biology.

<span class="mw-page-title-main">Robert Clarke (academic)</span> Northern Irish cancer researcher

Robert Clarke is a Northern Irish cancer researcher and academic administrator. He is the executive director of The Hormel Institute, a professor of biochemistry, Molecular Biology and Biophysics at the University of Minnesota, and an adjunct professor of oncology at Georgetown University.

<span class="mw-page-title-main">Pure apocrine carcinoma of the breast</span> Medical condition

Pure apocrine carcinoma of the breast (PACB) is a rare carcinoma derived from the epithelial cells in the lactiferous ducts of the mammary gland. The mammary gland is an apocrine gland. Its lactiferous ducts have two layers of epithelial cells, a luminal layer which faces the duct's lumen and a basal layer which lies beneath the luminal layer. There are at least four subtypes of epithelial cells in these ducts: luminal progenitor cells and luminal mature cells which reside in the luminal layer and mammary stem cells and basal cells which reside in the basal layer. Examination of the genes expressed in PACB cancer cells indicate that most of these tumors consist of cells derived from luminal cells but a minority of these tumors consist of cells derived from basal cells.

References

  1. Lee, Adrian V.; et al. (1 July 2015). "MCF-7 Cells—Changing the Course of Breast Cancer Research and Care for 45 Years". Journal of the National Cancer Institute. 107 (7): djv073. doi: 10.1093/jnci/djv073 . PMID   25828948.
  2. 1 2 3 Soule, HD; Vazquez J; Long A; Albert S; Brennan M. (1973). "A human cell line from a pleural effusion derived from a breast carcinoma". Journal of the National Cancer Institute . 51 (5): 1409–1416. doi:10.1093/jnci/51.5.1409. PMID   4357757.
  3. http://www.cancer.gov "NCI Cancer Bulletin for April 29, 2008 - National Cancer Institute". Archived from the original on 2010-05-27. Retrieved 2010-04-28. Retrieved on 2010-04-28
  4. Glodek, Cass, Ph.D., "A History of the Michigan Cancer Foundation, the Beginnings & Growth of Detroit's Anticancer Movement," 1990, page 68, Michigan Cancer Foundation, Detroit.
  5. Lee, A. V.; Oesterreich, S.; Davidson, N. E. (2015-03-31). "MCF-7 Cells--Changing the Course of Breast Cancer Research and Care for 45 Years". JNCI Journal of the National Cancer Institute. 107 (7): djv073. doi:10.1093/jnci/djv073. ISSN   0027-8874.
  6. 1 2 Levenson, AS; Jordan VC. (1997). "MCF-7: the first hormone-responsive breast cancer cell line". Cancer Research . 57 (15): 3071–3078. PMID   9242427.
  7. 1 2 Lacroix, M; Leclercq G. (2004). "Relevance of breast cancer cell lines as models for breast tumours: an update". Breast Research and Treatment . 83 (3): 249–289. doi:10.1023/B:BREA.0000014042.54925.cc. PMID   14758095. S2CID   207628369.
  8. 1 2 Comşa, Şerban; Cîmpean, Anca Maria; Raica, Marius (2015-06-01). "The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research". Anticancer Research. 35 (6): 3147–3154. ISSN   0250-7005.
  9. Ross, DT; Perou CM. (2001). "A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines". Disease Markers. 17 (2): 99–109. doi: 10.1155/2001/850531 . PMC   3850857 . PMID   11673656.
  10. Charafe-Jauffret, E; Ginestier C; Monville F; Finetti P; Adelaide J; Cervera N; Fekairi S; Xerri L; Jacquemier J; Birnbaum D; Bertucci F. (2006). "Gene expression profiling of breast cell lines identifies potential new basal markers". Oncogene . 25 (15): 2273–2284. doi:10.1038/sj.onc.1209254. PMID   16288205.
  11. Lacroix, M; Toillon RA; Leclercq G. (2006). "p53 and breast cancer, an update". Endocrine-Related Cancer . 13 (2). Bioscientifica: 293–325. doi: 10.1677/erc.1.01172 . PMID   16728565.
  12. Fanelli, Alex (2016). "MCF-7 Cells: human breast adenocarcinoma cell line" . Retrieved 3 December 2017.
  13. Sflomos, George; Dormoy, Valerian; Metsalu, Tauno; Jeitziner, Rachel; Battista, Laura; Scabia, Valentina; Raffoul, Wassim; Delaloye, Jean-Francois; Treboux, Assya (2016). "A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response". Cancer Cell. 29 (3): 407–422. doi: 10.1016/j.ccell.2016.02.002 . PMID   26947176.
  14. Mansara, Prakash P.; Deshpande, Rashmi A.; Vaidya, Milind M.; Kaul-Ghanekar, Ruchika (1 September 2015). "Differential Ratios of Omega Fatty Acids (AA/EPA+DHA) Modulate Growth, Lipid Peroxidation and Expression of Tumor Regulatory MARBPs in Breast Cancer Cell Lines MCF7 and MDA-MB-231". PLOS ONE. 10 (9): e0136542. Bibcode:2015PLoSO..1036542M. doi: 10.1371/journal.pone.0136542 . ISSN   1932-6203. PMC   4556657 . PMID   26325577.
  15. Cosmic. "COSMIC: Sample overview for 1289391". cancer.sanger.ac.uk. Retrieved 2017-05-10.
  16. Vasudevan, Krishna M.; Barbie, David A.; Davies, Michael A.; Rabinovsky, Rosalia; McNear, Chontelle J.; Kim, Jessica J.; Hennessy, Bryan T.; Tseng, Hsiuyi; Pochanard, Panisa (2009-07-07). "AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer". Cancer Cell. 16 (1): 21–32. doi:10.1016/j.ccr.2009.04.012. ISSN   1878-3686. PMC   2752826 . PMID   19573809.